Magrolimab

Unassigned

New Medicines

Myelodysplastic syndromes (MDS)

Information

New molecular entity
Gilead Sciences
Gilead Sciences

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Anti-CD47 monoclonal antibody and macrophage checkpoint inhibitor
MDS is a type of cancer caused by poorly formed or dysfunctional blood cells in the bone marrow. Approximately 15,000 people are diagnosed with MDS in the U.S. each year, and no new treatments have been approved in 14 years. The average survival rate for those with lower-risk MDS is six years and approximately 18 months for those with higher-risk MDS [1].
Myelodysplastic syndromes (MDS)
Intravenous